Contact
searchSearch
HMP Global

News

News
FDA Issues Class II Recall for Peritoneal Dialysis Solutions Due to Potential Sterility Breach
05/07/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for Fresenius DELFLEX peritoneal dialysis solutions due to potential bag leaks compromising sterility, affecting more than 80 000 units used in renal care.
The US Food and Drug Administration (FDA) has issued a Class II recall for Fresenius DELFLEX peritoneal dialysis solutions due to potential bag leaks compromising sterility, affecting more than 80 000 units used in renal care.
The US Food and Drug...
05/07/2026
Pharmacy Learning Network
News
Lubricant Eye Drops Under Class II Recall for Sterility Concerns
05/07/2026
Hannah Musick
A class II recall has been issued for FRESHKOTE Lubricant Eye Drops due to sterility assurance concerns, affecting more than 50 000 units used for dry eye relief.
A class II recall has been issued for FRESHKOTE Lubricant Eye Drops due to sterility assurance concerns, affecting more than 50 000 units used for dry eye relief.
A class II recall has been...
05/07/2026
Pharmacy Learning Network
News
Buspirone Tablets Recalled for Subpotency
05/07/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class III recall for buspirone tablets due to subpotency, potentially affecting treatment effectiveness.
The US Food and Drug Administration (FDA) has issued a Class III recall for buspirone tablets due to subpotency, potentially affecting treatment effectiveness.
The US Food and Drug...
05/07/2026
Pharmacy Learning Network
PharmLaw
North Carolina Reaches $11 Million EpiPen Settlement Over Pricing Practices
05/06/2026
Grace Taylor, MS, MA
North Carolina secured an $11 million settlement with Mylan over alleged EpiPen pricing and rebate practices that impacted Medicaid and state health plan costs.
North Carolina secured an $11 million settlement with Mylan over alleged EpiPen pricing and rebate practices that impacted Medicaid and state health plan costs.
North Carolina secured an $11...
05/06/2026
Pharmacy Learning Network
PharmLaw
Purdue Pharma Sentenced in Federal Opioid Case, Finalizing Fraud and Kickback Conspiracy Resolution
04/29/2026
Grace Taylor, MS, MA
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal...
04/29/2026
Pharmacy Learning Network
PharmLaw
Drug Lobby Challenges Washington State 340B Pharmacy Law
04/27/2026
Grace Taylor, MS, MA
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade...
04/27/2026
Pharmacy Learning Network
News
Memantine Hydrochloride Capsules Recalled for Failed Dissolution Specifications
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Semaglutide-Glycine-Cyanocobalamin Injectables Recalled for Lack of Sterility Assurance
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Essential Calming Skin Gel Recalled for Subpotent Drug
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
PharmLaw
Executive Order Targets Accelerated Development and Access Pathways for Psychedelic Therapies in Mental Health
04/21/2026
Hannah Musick
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs...
04/21/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use